For executives of Lexicon Pharmaceuticals Inc., the missed primary endpoint in the phase IIb Progress study testing pilavapadin, its non-opioid candidate, in adults with moderate to severe diabetic ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Vertex Pharmaceuticals Incorporated (Nasdaq ... highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well ...

The additive manufacturing sector continues to show near-limitless potential. Innovations have taken 3D printers from creating customized figurines all the way to printing entire neighborhoods, ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

There are plenty of great investment alternatives in the healthcare sector. You won't need a boatload of money to get started ...

While Blake Lively has kept a low profile, her co-star Anna Kendrick isn’t shying away from the cameras, even amid all the Simple Favor drama rumors. In fact, she just made a rare red carpet outing, ...

A Texas teen accused in an October 2024 murder has been released from police custody after posting bond, which was dramatically reduced from $800,000 to $100 per charge. Who would've thought that the ...

3. CAS Reg. No. 163222-33-1. Suzetrigine 1 is a newly registered nonopioid pain medication. It was first described in world patent application WO2021113627 (2021) to inventor Steven Durrant at Vertex ...

Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.